Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
An2 Therapeutics Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, indicating a diversified prosecution landscape for the company's current filings.
The busiest examiner, BURKETT, DANIEL JOHN, is handling 1 pending office action. With 2 examiners each managing a single case, the portfolio's immediate workload is evenly distributed across different administrative sections of the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18716814 | COMBINATIONS | BURKETT, DANIEL JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18716814 | COMBINATIONS | BURKETT, DANIEL JOHN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18716814 | COMBINATIONS | BURKETT, DANIEL JOHN | 1624 | §103§112 | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18716804 | NON-TUBERCULOSIS MYCOBACTERIA INFECTION TREATMENT | NOLAN, JASON MICHAEL | 1623 | §103 | Non-Final OA | — | Pending | Jun 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAn2 Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Daniel John Burkett has the most, with 1 of An2 Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
